Adverum Biotechnologies, Inc.
ADVM
$3.08
$0.051.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 1.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 1.00M | -- |
| Cost of Revenue | 37.13M | 28.75M | 24.10M | 20.44M | 17.10M |
| Gross Profit | -37.13M | -28.75M | -24.10M | -19.44M | -17.10M |
| SG&A Expenses | 12.73M | 19.47M | 38.12M | 9.78M | 15.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.86M | 48.22M | 62.22M | 30.22M | 32.90M |
| Operating Income | -49.86M | -48.22M | -62.22M | -29.22M | -32.90M |
| Income Before Tax | -49.19M | -47.02M | -60.53M | -27.13M | -30.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.19M | -47.02M | -60.53M | -27.13M | -30.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.19M | -47.02M | -60.53M | -27.13M | -30.50M |
| EBIT | -49.86M | -48.22M | -62.22M | -29.22M | -32.90M |
| EBITDA | -49.32M | -47.54M | -61.41M | -28.33M | -31.95M |
| EPS Basic | -2.34 | -2.25 | -2.90 | -1.30 | -1.46 |
| Normalized Basic EPS | -1.46 | -1.40 | -1.81 | -0.81 | -0.91 |
| EPS Diluted | -2.34 | -2.25 | -2.90 | -1.30 | -1.46 |
| Normalized Diluted EPS | -1.46 | -1.40 | -1.81 | -0.81 | -0.91 |
| Average Basic Shares Outstanding | 21.01M | 20.94M | 20.90M | 20.88M | 20.85M |
| Average Diluted Shares Outstanding | 21.01M | 20.94M | 20.90M | 20.88M | 20.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |